Oppenheimer Reiterates Outperform Rating on Trevi Therapeutics (TRVI)

September 25, 2026 6:03 AM

Oppenheimer analyst Leland Gershall reiterated an Outperform rating and $25.00 price target on Trevi Therapeutics (NASDAQ: TRVI).The analyst commented: "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found